Literature DB >> 3998720

Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale.

R D Lane, W M Glazer, T E Hansen, W H Berman, S I Kramer.   

Abstract

Over a 10-month period, 33 patients with tardive dyskinesia (TD) were evaluated with the Abnormal Involuntary Movement Scale (AIMS) simultaneously and independently by two experienced and two inexperienced raters. The experienced raters generally had higher levels of agreement and their scores were more consistent over time. It is concluded that experience with TD influences AIMS inter-rater reliability and that it is useful to differentiate TD movements into the dimensions of quality, frequency, and amplitude, dimensions not currently used in the AIMS. The usefulness and difficulty of developing more specific guidelines for AIMS ratings are discussed.

Entities:  

Mesh:

Year:  1985        PMID: 3998720     DOI: 10.1097/00005053-198506000-00005

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  32 in total

1.  The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study.

Authors:  Paul E Bebbington; Matthias Angermeyer; Jean-Michel Azorin; Traolach Brugha; Reinhold Kilian; Sonia Johnson; Mondher Toumi; Asa Kornfeld
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-09       Impact factor: 4.328

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Effectiveness evaluation of a pharmacist-driven monitoring database for tardive dyskinesia.

Authors:  Lauren A Diefenderfer; Leigh Anne Nelson; Ellie Elliott; Yifei Liu; Courtney Iuppa; Elizabeth Winans; Roger W Sommi
Journal:  Hosp Pharm       Date:  2014-06

4.  Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.

Authors:  Christoph U Correll; Linmarie Sikich; Gloria Reeves; Jacqueline Johnson; Courtney Keeton; Marina Spanos; Sandeep Kapoor; Kristin Bussell; Leslie Miller; Tara Chandrasekhar; Eva M Sheridan; Sara Pirmohamed; Shauna P Reinblatt; Cheryl Alderman; Abigail Scheer; Irmgard Borner; Terrence C Bethea; Sarah Edwards; Robert M Hamer; Mark A Riddle
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

5.  Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.

Authors:  Douglas L Noordsy; Shirley M Glynn; Catherine A Sugar; Christopher D O'Keefe; Stephen R Marder
Journal:  J Psychiatr Res       Date:  2017-09-08       Impact factor: 4.791

6.  Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia - A Reference Guide.

Authors: 
Journal:  Psychopharmacol Bull       Date:  2017-08-01

7.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

8.  The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Authors:  S Kutcher; G Papatheodorou; S Reiter; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

Review 9.  Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.

Authors:  Joseph M Pierre
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

10.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.